Phenylacetylglutamine is associated with the degree of coronary atherosclerotic severity assessed by coronary computed tomographic angiography in patients with suspected coronary artery disease.

Abstract

BACKGROUND AND AIMS\nPhenylacetylglutamine (PAG), a gut microbiota metabolite, has recently been found to be associated with major adverse cardiovascular events. In this study, we analyzed the relationship between plasma PAG and coronary atherosclerotic severity assessed by coronary computed tomographic angiography (CCTA).\n\n\nMETHODS\nWe enrolled consecutive patients with suspected coronary artery disease (CAD) who underwent CCTA. Plasma PAG was measured by mass spectrometry. Coronary atherosclerotic severity was evaluated based on plaque burden and plaque vulnerability. Plaque burden was quantified as percent atheroma volume (PAV), CCTA-derived SYNTAX score (CT-SYNTAX) and CAD reporting and data system score (CAD-RADS). Plaque vulnerability was evaluated by the presence of adverse characteristics.\n\n\nRESULTS\nA total of 686 patients were enrolled. The patients were divided into two groups based on median plasma PAG (3.25\xa0μM). A correlation was found between plasma PAG and PAV (r\xa0=\xa00.499, p\xa0<\xa00.01). Patients with obstructive CAD (CAD-RADS>3) and high coronary lesion complexity (CT-SYNTAX≥23) had higher plasma PAG (2.04 vs. 3.8\xa0μM and 2.85 vs. 4.49\xa0μM, respectively; p\xa0<\xa00.01 for all). After adjustment for confounding factors, plasma PAG remained associated with PAV (β: 0.98, p\xa0<\xa00.01), and patients in the higher PAG group had higher risks of obstructive CAD (odds ratio [OR]: 1.88, p\xa0<\xa00.01) and high coronary lesion complexity (OR: 1.47; p\xa0<\xa00.01). In addition, a high plasma PAG level (≥3.25\xa0μM) was not an independent predictor of the presence of high-risk plaques.\n\n\nCONCLUSIONS\nThere was an independent association between plasma PAG levels and the coronary atherosclerotic burden among patients with suspected CAD.